Immunogenicity to Biologics: Mechanisms, Prediction and Reduction
- 29 August 2012
- journal article
- review article
- Published by Walter de Gruyter GmbH in Archivum Immunologiae et Therapiae Experimentalis
- Vol. 60 (5) , 331-344
Abstract
Currently, there is a significant rise in the development and clinical use of a unique class of pharmaceuticals termed as Biopharmaceuticals or Biologics, in the management of a range of disease conditions with, remarkable therapeutic benefits. However, there is an equally growing concern regarding development of adverse effects like immunogenicity in the form of anti-drug antibodies (ADA) production and hypersensitivity. Immunogenicity to biologics represents a significant hurdle in the continuing therapy of patients in a number of disease settings. Efforts focussed on the identification of factors that contribute towards the onset of immunogenic response to biologics have led to reductions in the incidence of immunogenicity. An in-depth understanding of the cellular and molecular mechanism underpinning immunogenic responses will likely improve the safety profile of biologics. This review addresses the mechanistic basis of ADA generation to biologics, with emphasis on the role of antigen processing and presentation in this process. The article also addresses the potential contribution of complement system in augmenting or modulating this response. Identifying specific factors that influences processing and presentation of biologic-derived antigens in different genotype and disease background may offer additional options for intervention in the immunogenic process and consequently, the management of immunogenicity to biologics.Keywords
This publication has 165 references indexed in Scilit:
- Oxidized and Aggregated Recombinant Human Interferon Beta is Immunogenic in Human Interferon Beta Transgenic MicePharmaceutical Research, 2011
- C5a receptor‐deficient dendritic cells promote induction of Treg and Th17 cellsEuropean Journal of Immunology, 2010
- Effect of Route of Administration of Human Recombinant Factor VIII on Its Immunogenicity in Hemophilia A MiceJournal of Pharmaceutical Sciences, 2009
- HLA-DRB1∗0401 and HLA-DRB1∗0408 Are Strongly Associated with the Development of Antibodies against Interferon-β Therapy in Multiple SclerosisThe American Journal of Human Genetics, 2008
- Predicting linear B‐cell epitopes using string kernelsJournal of Molecular Recognition, 2008
- Locally Produced Complement Fragments C5a and C3a Provide Both Costimulatory and Survival Signals to Naive CD4+ T CellsImmunity, 2008
- Aging and the dendritic cell system: Implications for cancerCritical Reviews in Oncology/Hematology, 2007
- Anaphylaxis: Lessons from mouse modelsJournal of Allergy and Clinical Immunology, 2007
- A systematic bioinformatics approach for selection of epitope-based vaccine targetsCellular Immunology, 2006
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006